Pistachios may reduce risk of heart-disease

10 November 2008

A diet including pistachio nuts results in significantly-reduced markers of inflammation at the cellular level, when compared to the average US diet, according to new data presented at the American Diabetic Association's Food & Nutrition Conference & Expo in Chicago.

A randomized, crossover, controlled-feeding study, by Penn State University, examined changes in inflammation-related gene expression and evaluated the effects of pistachio-rich diets on heart disease risk factors in subjects with moderately-elevated low-density lipoprotein cholesterol. Participants followed three diets, two with different levels of pistachio consumption (around 1.5oz and 3.0oz) and one without.

The results support recent studie conducted both by Penn State and the University of Toronto, Canada, that show a diet rich in pistachios helps to improve a range of heart disease risk factors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight